Clorazepate Dipotassium
Loading...Clorazepate Dipotassium Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Clorazepate dipotassium tablets are not recommended for use in depressive neuroses or in psychotic reactions.
Because of the lack of sufficient clinical experience, clorazepate dipotassium tablets are not recommended for use in patients less than 9 years of age.
Patients taking clorazepate dipotassium tablets should be cautioned against engaging in hazardous occupations requiring mental alertness, such as operating dangerous machinery including motor vehicles.
Since clorazepate dipotassium has a central nervous system depressant effect, patients should be advised against the simultaneous use of other CNS depressant drugs, and cautioned that the effects of alcohol may be increased.
Withdrawal symptoms (similar in character to those noted with barbiturates and alcohol) have occurred following abrupt discontinuance of clorazepate. Withdrawal symptoms associated with the abrupt discontinuation of benzodiazepines have included convulsions, delirium, tremor, abdominal and muscle cramps, vomiting, sweating, nervousness, insomnia, irritability, diarrhea, and memory impairment. The more severe withdrawal symptoms have usually been limited to those patients who had received excessive doses over an extended period of time. Generally milder withdrawal symptoms have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. Consequently, after extended therapy, abrupt discontinuation of clorazepate should generally be avoided and a gradual dosage tapering schedule followed.
Caution should be observed in patients who are considered to have a psychological potential for drug dependence.
Evidence of drug dependence has been observed in dogs and rabbits which was characterized by convulsive seizures when the drug was abruptly withdrawn or the dose was reduced; the syndrome in dogs could be abolished by administration of clorazepate.
Antiepileptic drugs (AEDs), including clorazepate dipotassium, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.
Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide.
The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed. Table 1 shows absolute and relative risk by indication for all evaluated AEDs.
| Indication | Placebo Patients with Events Per 1,000 Patients |
Drug Patients with Events Per 1,000 Patients |
Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients |
Risk Difference: Additional Drug Patients with Events Per 1,000 Patients |
| Epilepsy | 1 | 3.4 | 3.5 | 2.4 |
| Psychiatric | 5.7 | 8.5 | 1.5 | 2.9 |
| Other | 1 | 1.8 | 1.9 | 0.9 |
| Total | 2.4 | 4.3 | 1.8 | 1.9 |
The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.
Anyone considering prescribing clorazepate dipotassium or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.
Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.
An increased risk of congenital malformations associated with the use of minor tranquilizers (chlordiazepoxide, diazepam, and meprobamate) during the first trimester of pregnancy has been suggested in several studies. Clorazepate dipotassium, a benzodiazepine derivative, has not been studied adequately to determine whether it, too, may be associated with an increased risk of fetal abnormality. Because use of these drugs is rarely a matter of urgency, their use during this period should almost always be avoided. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. Patients should be advised that if they become pregnant during therapy or intend to become pregnant they should communicate with their physician about the desirability of discontinuing the drug.
To provide information regarding the effects of in utero exposure to clorazepate dipotassium, physicians are advised to recommend that pregnant patients taking clorazepate dipotassium enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/.
Clorazepate dipotassium tablets should not be given to nursing mothers since it has been reported that nordiazepam is excreted in human breast milk.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Clorazepate dipotassium tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.
Clorazepate dipotassium tablets are indicated as adjunctive therapy in the management of partial seizures.
The effectiveness of clorazepate dipotassium tablets in long-term management of anxiety, that is, more than 4 months, has not been assessed by systematic clinical studies. Long-term studies in epileptic patients, however, have shown continued therapeutic activity. The physician should reassess periodically the usefulness of the drug for the individual patient.
Clorazepate dipotassium tablets are indicated for the symptomatic relief of acute alcohol withdrawal.
History
There is currently no drug history available for this drug.
Other Information
Chemically, clorazepate dipotassium, USP is a benzodiazepine. The molecular formula is C16H11ClK2N2O4; the molecular weight is 408.92; 1H-1, 4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, potassium salt compound with potassium hydroxide (1:1) and the structural formula may be represented as follows:
The compound occurs as a fine, light yellow, practically odorless powder. It is insoluble in the common organic solvents, but very soluble in water. Aqueous solutions are unstable, clear, light yellow, and alkaline.
Clorazepate Dipotassium Tablets, USP for oral administration, contain 3.75 mg, 7.5 mg or 15 mg of clorazepate dipotassium, USP. In addition, each tablet contains the following inactive ingredients: croscarmellose sodium, magnesium oxide, magnesium stearate, microcrystalline cellulose, potassium carbonate, sodium chloride, sodium lauryl sulfate and the following coloring agents:
3.75 mg - FD&C Blue No. 2 Aluminum Lake
7.5 mg - FD&C Yellow No. 6 Aluminum Lake
Sources
Clorazepate Dipotassium Manufacturers
-
Pd-rx Pharmaceuticals, Inc.
![Clorazepate Dipotassium Tablet [Pd-rx Pharmaceuticals, Inc.]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Clorazepate Dipotassium | Pd-rx Pharmaceuticals, Inc.
For the Symptomatic Relief of AnxietyClorazepate dipotassium tablets are administered orally in divided doses. The usual daily dose is 30 mg. The dose should be adjusted gradually within the range of 15 mg to 60 mg daily in accordance with the response of the patient. In elderly or debilitated patients it is advisable to initiate treatment at a daily dose of 7.5 mg to 15 mg.
Clorazepate dipotassium tablets may also be administered in a single dose daily at bedtime; the recommended initial dose is 15 mg. After the initial dose, the response of the patient may require adjustment of subsequent dosage. Lower doses may be indicated in the elderly patient. Drowsiness may occur at the initiation of treatment and with dosage increment.
For the Symptomatic Relief of Acute Alcohol WithdrawalThe following dosage schedule is recommended:
1st 24 hours
(Day 1) 30 mg initially; followed by 30 mg to 60 mg in divided doses. 2nd 24 hours
(Day 2) 45 mg to 90 mg in divided doses. 3rd 24 hours
(Day 3) 22.5 mg to 45 mg in divided doses Day 4 15 mg to 30 mg in divided dosesThereafter, gradually reduce the daily dose to 7.5 mg to 15 mg. Discontinue drug therapy as soon as patient’s condition is stable.
The maximum recommended total daily dose is 90 mg. Avoid excessive reductions in the total amount of drug administered on successive days.
As an Adjunct to Antiepileptic DrugsIn order to minimize drowsiness, the recommended initial dosages and dosage increments should not be exceeded.
AdultsThe maximum recommended initial dose in patients over 12 years old is 7.5 mg three times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 90 mg/day.
Children: (9 to 12 years)The maximum recommended initial dose is 7.5 mg two times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 60 mg/day.
-
Rebel Distributors Corp
Clorazepate Dipotassium | Rebel Distributors Corp
For the symptomatic relief of anxietyClorazepate dipotassium tablets are administered orally in divided doses. The usual daily dose is 30 mg. The dose should be adjusted gradually within the range of 15 to 60 mg daily in accordance with the response of the patient. In elderly or debilitated patients it is advisable to initiate treatment at a daily dose of 7.5 to 15 mg.
Clorazepate dipotassium tablets may also be administered in a single dose daily at bedtime; the recommended initial dose is 15 mg. After the initial dose, the response of the patient may require adjustment of subsequent dosage. Lower doses may be indicated in the elderly patient. Drowsiness may occur at the initiation of treatment and with dosage increment.
For the symptomatic relief of acute alcohol withdrawalThe following dosage schedule is recommended
1st 24 hours
(Day 1) 30 mg initially, followed by 30 to 60 mg in divided doses 2nd 24 hours
(Day 2) 45 to 90 mg in divided doses 3rd 24 hours
(Day 3) 22.5 to 45 mg in divided doses Day 4 15 to 30 mg in divided dosesThereafter, gradually reduce the daily dose to 7.5 to 15 mg. Discontinue drug therapy as soon as patient's condition is stable.
The maximum recommended total daily dose is 90 mg. Avoid excessive reductions in the total amount of drug administered on successive days.
As an Adjunct to Antiepileptic DrugsIn order to minimize drowsiness, the recommended initial dosages and dosage increments should not be exceeded.
AdultsThe maximum recommended initial dose in patients over 12 years old is 7.5 mg three times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 90 mg/day.
Children (9-12 years)The maximum recommended initial dose is 7.5 mg two times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 60 mg/day.
-
Physicians Total Care, Inc.
Clorazepate Dipotassium | Physicians Total Care, Inc.
For the Symptomatic Relief of AnxietyClorazepate dipotassium tablets are administered orally in divided doses. The usual daily dose is 30 mg. The dose should be adjusted gradually within the range of 15 mg to 60 mg daily in accordance with the response of the patient. In elderly or debilitated patients it is advisable to initiate treatment at a daily dose of 7.5 mg to 15 mg.
Clorazepate dipotassium tablets may also be administered in a single dose daily at bedtime; the recommended initial dose is 15 mg. After the initial dose, the response of the patient may require adjustment of subsequent dosage. Lower doses may be indicated in the elderly patient. Drowsiness may occur at the initiation of treatment and with dosage increment.
For the Symptomatic Relief of Acute Alcohol WithdrawalThe following dosage schedule is recommended:
1st 24 hours
(Day 1) 30 mg initially; followed by 30 mg to 60 mg in divided doses. 2nd 24 hours
(Day 2) 45 mg to 90 mg in divided doses. 3rd 24 hours
(Day 3) 22.5 mg to 45 mg in divided doses Day 4 15 mg to 30 mg in divided dosesThereafter, gradually reduce the daily dose to 7.5 mg to 15 mg. Discontinue drug therapy as soon as patient’s condition is stable.
The maximum recommended total daily dose is 90 mg. Avoid excessive reductions in the total amount of drug administered on successive days.
As an Adjunct to Antiepileptic DrugsIn order to minimize drowsiness, the recommended initial dosages and dosage increments should not be exceeded.
AdultsThe maximum recommended initial dose in patients over 12 years old is 7.5 mg three times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 90 mg/day.
Children: (9 to 12 years)The maximum recommended initial dose is 7.5 mg two times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 60 mg/day.
-
Contract Pharmacy Services-pa
Clorazepate Dipotassium | Contract Pharmacy Services-pa
For the symptomatic relief of anxietyClorazepate dipotassium tablets are administered orally in divided doses. The usual daily dose is 30 mg. The dose should be adjusted gradually within the range of 15 to 60 mg daily in accordance with the response of the patient. In elderly or debilitated patients it is advisable to initiate treatment at a daily dose of 7.5 to 15 mg.
Clorazepate dipotassium tablets may also be administered in a single dose daily at bedtime; the recommended initial dose is 15 mg. After the initial dose, the response of the patient may require adjustment of subsequent dosage. Lower doses may be indicated in the elderly patient. Drowsiness may occur at the initiation of treatment and with dosage increment.
For the symptomatic relief of acute alcohol withdrawalThe following dosage schedule is recommended
1st 24 hours
(Day 1) 30 mg initially, followed by 30 to 60 mg in divided doses 2nd 24 hours
(Day 2) 45 to 90 mg in divided doses 3rd 24 hours
(Day 3) 22.5 to 45 mg in divided doses Day 4 15 to 30 mg in divided dosesThereafter, gradually reduce the daily dose to 7.5 to 15 mg. Discontinue drug therapy as soon as patient's condition is stable.
The maximum recommended total daily dose is 90 mg. Avoid excessive reductions in the total amount of drug administered on successive days.
As an Adjunct to Antiepileptic DrugsIn order to minimize drowsiness, the recommended initial dosages and dosage increments should not be exceeded.
AdultsThe maximum recommended initial dose in patients over 12 years old is 7.5 mg three times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 90 mg/day.
Children (9-12 years)The maximum recommended initial dose is 7.5 mg two times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 60 mg/day.
-
Remedyrepack Inc.
Clorazepate Dipotassium | Remedyrepack Inc.
For the symptomatic relief of anxiety:
Clorazepate dipotassium tablets are administered orally in divided doses. The usual daily dose is 30 mg. The dose should be adjusted gradually within the range of 15 to 60 mg daily in accordance with the response of the patient. In elderly or debilitated patients it is advisable to initiate treatment at a daily dose of 7.5 to 15 mg.
Clorazepate dipotassium tablets may also be administered in a single dose daily at bedtime; the recommended initial dose is 15 mg. After the initial dose, the response of the patient may require adjustment of subsequent dosage. Lower doses may be indicated in the elderly patient. Drowsiness may occur at the initiation of treatment and with dosage increment.
For the symptomatic relief of acute alcohol withdrawal:
The following dosage schedule is recommended:
1st 24 hours (Day 1) 30 mg initially; followed by 30 to 60 mg in divided doses 2nd 24 hours (Day 2) 45 to 90 mg in divided doses 3rd 24 hours (Day 3) 22.5 to 45 mg in divided doses Day 4 15 to 30 mg in divided dosesThereafter, gradually reduce the daily dose to 7.5 to 15 mg. Discontinue drug therapy as soon as patient's condition is stable.
The maximum recommended total daily dose is 90 mg. Avoid excessive reductions in the total amount of drug administered on successive days.
As an Adjunct to Antiepileptic Drugs:
In order to minimize drowsiness, the recommended initial dosages and dosage increments should not be exceeded.
Adults: The maximum recommended initial dose in patients over 12 years old is 7.5 mg three times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 90 mg/day.
Children (9 to 12 years): The maximum recommended initial dose is 7.5 mg two times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 60 mg/day.
-
Taro Pharmaceuticals U.s.a., Inc.
Clorazepate Dipotassium | Taro Pharmaceuticals U.s.a., Inc.
For the symptomatic relief of anxietyClorazepate dipotassium tablets are administered orally in divided doses. The usual daily dose is 30 mg. The dose should be adjusted gradually within the range of 15 to 60 mg daily in accordance with the response of the patient. In elderly or debilitated patients it is advisable to initiate treatment at a daily dose of 7.5 to 15 mg.
Clorazepate dipotassium tablets may also be administered in a single dose daily at bedtime; the recommended initial dose is 15 mg. After the initial dose, the response of the patient may require adjustment of subsequent dosage. Lower doses may be indicated in the elderly patient. Drowsiness may occur at the initiation of treatment and with dosage increment.
For the symptomatic relief of acute alcohol withdrawalThe following dosage schedule is recommended:
1st 24 hours (Day 1) 30 mg initially; followed by 30 to 60 mg in divided doses 2nd 24 hours (Day 2) 45 to 90 mg in divided doses 3rd 24 hours (Day 3) 22.5 to 45 mg in divided doses Day 4 15 to 30 mg in divided dosesThereafter, gradually reduce the daily dose to 7.5 to 15 mg. Discontinue drug therapy as soon as patient's condition is stable.
The maximum recommended total daily dose is 90 mg. Avoid excessive reductions in the total amount of drug administered on successive days.
As an Adjunct to Antiepileptic DrugsIn order to minimize drowsiness, the recommended initial dosages and dosage increments should not be exceeded.
AdultsThe maximum recommended initial dose in patients over 12 years old is 7.5 mg three times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 90 mg/day.
Children (9-12 years)The maximum recommended initial dose is 7.5 mg two times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 60 mg/day.
-
Pd-rx Pharmaceuticals, Inc.
Clorazepate Dipotassium | Pd-rx Pharmaceuticals, Inc.
For the Symptomatic Relief of AnxietyClorazepate dipotassium tablets are administered orally in divided doses. The usual daily dose is 30 mg. The dose should be adjusted gradually within the range of 15 mg to 60 mg daily in accordance with the response of the patient. In elderly or debilitated patients it is advisable to initiate treatment at a daily dose of 7.5 mg to 15 mg.
Clorazepate dipotassium tablets may also be administered in a single dose daily at bedtime; the recommended initial dose is 15 mg. After the initial dose, the response of the patient may require adjustment of subsequent dosage. Lower doses may be indicated in the elderly patient. Drowsiness may occur at the initiation of treatment and with dosage increment.
For the Symptomatic Relief of Acute Alcohol WithdrawalThe following dosage schedule is recommended:
1st 24 hours
(Day 1) 30 mg initially; followed by 30 mg to 60 mg in divided doses. 2nd 24 hours
(Day 2) 45 mg to 90 mg in divided doses. 3rd 24 hours
(Day 3) 22.5 mg to 45 mg in divided doses Day 4 15 mg to 30 mg in divided dosesThereafter, gradually reduce the daily dose to 7.5 mg to 15 mg. Discontinue drug therapy as soon as patient’s condition is stable.
The maximum recommended total daily dose is 90 mg. Avoid excessive reductions in the total amount of drug administered on successive days.
As an Adjunct to Antiepileptic DrugsIn order to minimize drowsiness, the recommended initial dosages and dosage increments should not be exceeded.
AdultsThe maximum recommended initial dose in patients over 12 years old is 7.5 mg three times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 90 mg/day.
Children: (9 to 12 years)The maximum recommended initial dose is 7.5 mg two times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 60 mg/day.
-
Pd-rx Pharmaceuticals, Inc.
Clorazepate Dipotassium | Pd-rx Pharmaceuticals, Inc.
For the Symptomatic Relief of AnxietyClorazepate dipotassium tablets are administered orally in divided doses. The usual daily dose is 30 mg. The dose should be adjusted gradually within the range of 15 mg to 60 mg daily in accordance with the response of the patient. In elderly or debilitated patients it is advisable to initiate treatment at a daily dose of 7.5 mg to 15 mg.
Clorazepate dipotassium tablets may also be administered in a single dose daily at bedtime; the recommended initial dose is 15 mg. After the initial dose, the response of the patient may require adjustment of subsequent dosage. Lower doses may be indicated in the elderly patient. Drowsiness may occur at the initiation of treatment and with dosage increment.
For the Symptomatic Relief of Acute Alcohol WithdrawalThe following dosage schedule is recommended:
1st 24 hours
(Day 1) 30 mg initially; followed by 30 mg to 60 mg in divided doses. 2nd 24 hours
(Day 2) 45 mg to 90 mg in divided doses. 3rd 24 hours
(Day 3) 22.5 mg to 45 mg in divided doses Day 4 15 mg to 30 mg in divided dosesThereafter, gradually reduce the daily dose to 7.5 mg to 15 mg. Discontinue drug therapy as soon as patient’s condition is stable.
The maximum recommended total daily dose is 90 mg. Avoid excessive reductions in the total amount of drug administered on successive days.
As an Adjunct to Antiepileptic DrugsIn order to minimize drowsiness, the recommended initial dosages and dosage increments should not be exceeded.
AdultsThe maximum recommended initial dose in patients over 12 years old is 7.5 mg three times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 90 mg/day.
Children: (9 to 12 years)The maximum recommended initial dose is 7.5 mg two times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 60 mg/day.
-
Mylan Pharmaceuticals Inc.
Clorazepate Dipotassium | Mylan Pharmaceuticals Inc.
For the Symptomatic Relief of AnxietyClorazepate dipotassium tablets are administered orally in divided doses. The usual daily dose is 30 mg. The dose should be adjusted gradually within the range of 15 mg to 60 mg daily in accordance with the response of the patient. In elderly or debilitated patients it is advisable to initiate treatment at a daily dose of 7.5 mg to 15 mg.
Clorazepate dipotassium tablets may also be administered in a single dose daily at bedtime; the recommended initial dose is 15 mg. After the initial dose, the response of the patient may require adjustment of subsequent dosage. Lower doses may be indicated in the elderly patient. Drowsiness may occur at the initiation of treatment and with dosage increment.
For the Symptomatic Relief of Acute Alcohol WithdrawalThe following dosage schedule is recommended:
1st 24 hours
(Day 1)30 mg initially; followed by 30 mg to 60 mg in divided doses.
2nd 24 hours
(Day 2)45 mg to 90 mg in divided doses.
3rd 24 hours
(Day 3)22.5 mg to 45 mg in divided doses
Day 4
15 mg to 30 mg in divided doses
Thereafter, gradually reduce the daily dose to 7.5 mg to 15 mg. Discontinue drug therapy as soon as patient’s condition is stable.
The maximum recommended total daily dose is 90 mg. Avoid excessive reductions in the total amount of drug administered on successive days.
As an Adjunct to Antiepileptic DrugsIn order to minimize drowsiness, the recommended initial dosages and dosage increments should not be exceeded.
AdultsThe maximum recommended initial dose in patients over 12 years old is 7.5 mg three times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 90 mg/day.
Children: (9 to 12 years)The maximum recommended initial dose is 7.5 mg two times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 60 mg/day.
-
Ranbaxy Pharmaceuticals Inc.
Clorazepate Dipotassium | Ranbaxy Pharmaceuticals Inc.
For the symptomatic relief of anxiety: Clorazepate dipotassium tablets are administered orally in divided doses. The usual daily dose is 30 mg. The dose should be adjusted gradually within the range of 15 to 60 mg daily in accordance with the response of the patient. In elderly or debilitated patients it is advisable to initiate treatment at a daily dose of 7.5 to 15 mg.
Clorazepate dipotassium tablets may also be administered in a single dose daily at bedtime; the recommended initial dose is 15 mg. After the initial dose, the response of the patient may require adjustment of subsequent dosage. Lower doses may be indicated in the elderly patient. Drowsiness may occur at the initiation of treatment and with dosage increment.
For the symptomatic relief of acute alcohol withdrawal:
The following dosage schedule is recommended:
1st 24 hours (Day 1) 30 mg initially; followed by 30 to 60 mg in divided doses 2nd 24 hours (Day 2) 45 to 90 mg in divided doses 3rd 24 hours (Day 3) 22.5 to 45 mg in divided doses Day 4 15 to 30 mg in divided dosesThereafter, gradually reduce the daily dose to 7.5 to 15 mg. Discontinue drug therapy as soon as patient's condition is stable.
The maximum recommended total daily dose is 90 mg. Avoid excessive reductions in the total amount of drug administered on successive days.
As an Adjunct to Antiepileptic Drugs: In order to minimize drowsiness, the recommended initial dosages and dosage increments should not be exceeded.
Adults: The maximum recommended initial dose in patients over 12 years old is 7.5 mg three times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 90 mg/day.
Children (9 to 12 years): The maximum recommended initial dose is 7.5 mg two times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 60 mg/day.
-
Bryant Ranch Prepack
Clorazepate Dipotassium | Bryant Ranch Prepack
For the symptomatic relief of anxietyClorazepate dipotassium tablets are administered orally in divided doses. The usual daily dose is 30 mg. The dose should be adjusted gradually within the range of 15 to 60 mg daily in accordance with the response of the patient. In elderly or debilitated patients it is advisable to initiate treatment at a daily dose of 7.5 to 15 mg.
Clorazepate dipotassium tablets may also be administered in a single dose daily at bedtime; the recommended initial dose is 15 mg. After the initial dose, the response of the patient may require adjustment of subsequent dosage. Lower doses may be indicated in the elderly patient. Drowsiness may occur at the initiation of treatment and with dosage increment.
For the symptomatic relief of acute alcohol withdrawalThe following dosage schedule is recommended:
1st 24 hours (Day 1) 30 mg initially; followed by 30 to 60 mg in divided doses 2nd 24 hours (Day 2) 45 to 90 mg in divided doses 3rd 24 hours (Day 3) 22.5 to 45 mg in divided doses Day 4 15 to 30 mg in divided dosesThereafter, gradually reduce the daily dose to 7.5 to 15 mg. Discontinue drug therapy as soon as patient's condition is stable.
The maximum recommended total daily dose is 90 mg. Avoid excessive reductions in the total amount of drug administered on successive days.
As an Adjunct to Antiepileptic DrugsIn order to minimize drowsiness, the recommended initial dosages and dosage increments should not be exceeded.
AdultsThe maximum recommended initial dose in patients over 12 years old is 7.5 mg three times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 90 mg/day.
Children (9-12 years)The maximum recommended initial dose is 7.5 mg two times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 60 mg/day.
-
Bryant Ranch Prepack
Clorazepate Dipotassium | Bryant Ranch Prepack
For the symptomatic relief of anxiety: Clorazepate dipotassium tablets are administered orally in divided doses. The usual daily dose is 30 mg. The dose should be adjusted gradually within the range of 15 to 60 mg daily in accordance with the response of the patient. In elderly or debilitated patients it is advisable to initiate treatment at a daily dose of 7.5 to 15 mg.
Clorazepate dipotassium tablets may also be administered in a single dose daily at bedtime; the recommended initial dose is 15 mg. After the initial dose, the response of the patient may require adjustment of subsequent dosage. Lower doses may be indicated in the elderly patient. Drowsiness may occur at the initiation of treatment and with dosage increment.
For the symptomatic relief of acute alcohol withdrawal:
The following dosage schedule is recommended:
1st 24 hours (Day 1) 30 mg initially; followed by 30 to 60 mg in divided doses 2nd 24 hours (Day 2) 45 to 90 mg in divided doses 3rd 24 hours (Day 3) 22.5 to 45 mg in divided doses Day 4 15 to 30 mg in divided dosesThereafter, gradually reduce the daily dose to 7.5 to 15 mg. Discontinue drug therapy as soon as patient's condition is stable.
The maximum recommended total daily dose is 90 mg. Avoid excessive reductions in the total amount of drug administered on successive days.
As an Adjunct to Antiepileptic Drugs: In order to minimize drowsiness, the recommended initial dosages and dosage increments should not be exceeded.
Adults: The maximum recommended initial dose in patients over 12 years old is 7.5 mg three times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 90 mg/day.
Children (9 to 12 years): The maximum recommended initial dose is 7.5 mg two times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 60 mg/day.
-
Bryant Ranch Prepack
Clorazepate Dipotassium | Bryant Ranch Prepack
For the symptomatic relief of anxietyClorazepate dipotassium tablets are administered orally in divided doses. The usual daily dose is 30 mg. The dose should be adjusted gradually within the range of 15 to 60 mg daily in accordance with the response of the patient. In elderly or debilitated patients it is advisable to initiate treatment at a daily dose of 7.5 to 15 mg.
Clorazepate dipotassium tablets may also be administered in a single dose daily at bedtime; the recommended initial dose is 15 mg. After the initial dose, the response of the patient may require adjustment of subsequent dosage. Lower doses may be indicated in the elderly patient. Drowsiness may occur at the initiation of treatment and with dosage increment.
For the symptomatic relief of acute alcohol withdrawalThe following dosage schedule is recommended:
1st 24 hours (Day 1) 30 mg initially; followed by 30 to 60 mg in divided doses 2nd 24 hours (Day 2) 45 to 90 mg in divided doses 3rd 24 hours (Day 3) 22.5 to 45 mg in divided doses Day 4 15 to 30 mg in divided dosesThereafter, gradually reduce the daily dose to 7.5 to 15 mg. Discontinue drug therapy as soon as patient's condition is stable.
The maximum recommended total daily dose is 90 mg. Avoid excessive reductions in the total amount of drug administered on successive days.
As an Adjunct to Antiepileptic DrugsIn order to minimize drowsiness, the recommended initial dosages and dosage increments should not be exceeded.
AdultsThe maximum recommended initial dose in patients over 12 years old is 7.5 mg three times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 90 mg/day.
Children (9-12 years)The maximum recommended initial dose is 7.5 mg two times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 60 mg/day.
-
Pd-rx Pharmaceuticals, Inc.
Clorazepate Dipotassium | Pd-rx Pharmaceuticals, Inc.
For the symptomatic relief of anxiety: Clorazepate dipotassium tablets are administered orally in divided doses. The usual daily dose is 30 mg. The dose should be adjusted gradually within the range of 15 to 60 mg daily in accordance with the response of the patient. In elderly or debilitated patients it is advisable to initiate treatment at a daily dose of 7.5 to 15 mg.
Clorazepate dipotassium tablets may also be administered in a single dose daily at bedtime; the recommended initial dose is 15 mg. After the initial dose, the response of the patient may require adjustment of subsequent dosage. Lower doses may be indicated in the elderly patient. Drowsiness may occur at the initiation of treatment and with dosage increment.
For the symptomatic relief of acute alcohol withdrawal:
The following dosage schedule is recommended:
1st 24 hours (Day 1) 30 mg initially; followed by 30 to 60 mg in divided doses 2nd 24 hours (Day 2) 45 to 90 mg in divided doses 3rd 24 hours (Day 3) 22.5 to 45 mg in divided doses Day 4 15 to 30 mg in divided dosesThereafter, gradually reduce the daily dose to 7.5 to 15 mg. Discontinue drug therapy as soon as patient's condition is stable.
The maximum recommended total daily dose is 90 mg. Avoid excessive reductions in the total amount of drug administered on successive days.
As an Adjunct to Antiepileptic Drugs: In order to minimize drowsiness, the recommended initial dosages and dosage increments should not be exceeded.
Adults: The maximum recommended initial dose in patients over 12 years old is 7.5 mg three times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 90 mg/day.
Children (9 to 12 years): The maximum recommended initial dose is 7.5 mg two times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 60 mg/day.
-
A-s Medication Solutions Llc
Clorazepate Dipotassium | A-s Medication Solutions Llc
For the symptomatic relief of anxietyClorazepate dipotassium tablets are administered orally in divided doses. The usual daily dose is 30 mg. The dose should be adjusted gradually within the range of 15 to 60 mg daily in accordance with the response of the patient. In elderly or debilitated patients it is advisable to initiate treatment at a daily dose of 7.5 to 15 mg.
Clorazepate dipotassium tablets may also be administered in a single dose daily at bedtime; the recommended initial dose is 15 mg. After the initial dose, the response of the patient may require adjustment of subsequent dosage. Lower doses may be indicated in the elderly patient. Drowsiness may occur at the initiation of treatment and with dosage increment.
For the symptomatic relief of acute alcohol withdrawalThe following dosage schedule is recommended:
1st 24 hours (Day 1) 30 mg initially; followed by 30 to 60 mg in divided doses 2nd 24 hours (Day 2) 45 to 90 mg in divided doses 3rd 24 hours (Day 3) 22.5 to 45 mg in divided doses Day 4 15 to 30 mg in divided dosesThereafter, gradually reduce the daily dose to 7.5 to 15 mg. Discontinue drug therapy as soon as patient's condition is stable.
The maximum recommended total daily dose is 90 mg. Avoid excessive reductions in the total amount of drug administered on successive days.
As an Adjunct to Antiepileptic DrugsIn order to minimize drowsiness, the recommended initial dosages and dosage increments should not be exceeded.
AdultsThe maximum recommended initial dose in patients over 12 years old is 7.5 mg three times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 90 mg/day.
Children (9-12 years)The maximum recommended initial dose is 7.5 mg two times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 60 mg/day.
-
American Health Packaging
Clorazepate Dipotassium | American Health Packaging
For the symptomatic relief of anxietyClorazepate dipotassium tablets are administered orally in divided doses. The usual daily dose is 30 mg. The dose should be adjusted gradually within the range of 15 to 60 mg daily in accordance with the response of the patient. In elderly or debilitated patients it is advisable to initiate treatment at a daily dose of 7.5 to 15 mg.
Clorazepate dipotassium tablets may also be administered in a single dose daily at bedtime; the recommended initial dose is 15 mg. After the initial dose, the response of the patient may require adjustment of subsequent dosage. Lower doses may be indicated in the elderly patient. Drowsiness may occur at the initiation of treatment and with dosage increment.
For the symptomatic relief of acute alcohol withdrawalThe following dosage schedule is recommended:
1st 24 hours (Day 1)
30 mg initially; followed by 30 to 60 mg in divided doses
2nd 24 hours (Day 2)
45 to 90 mg in divided doses
3rd 24 hours (Day 3)
22.5 to 45 mg in divided doses
Day 4
15 to 30 mg in divided doses
Thereafter, gradually reduce the daily dose to 7.5 to 15 mg. Discontinue drug therapy as soon as patient's condition is stable.
The maximum recommended total daily dose is 90 mg. Avoid excessive reductions in the total amount of drug administered on successive days.
As an Adjunct to Antiepileptic DrugsIn order to minimize drowsiness, the recommended initial dosages and dosage increments should not be exceeded.
AdultsThe maximum recommended initial dose in patients over 12 years old is 7.5 mg three times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 90 mg/day.
Children (9-12 years)The maximum recommended initial dose is 7.5 mg two times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 60 mg/day.
![Clorazepate Dipotassium Tablet [Rebel Distributors Corp]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a6cc08b8-146e-430f-af39-8b866698b997&name=a6cc08b8-146e-430f-af39-8b866698b997-02.jpg)
![Clorazepate Dipotassium Tablet [Physicians Total Care, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=92a354fb-efb3-4ebf-acfa-1c258d8664a6&name=packagelabel01.jpg)
![Clorazepate Dipotassium Tablet [Contract Pharmacy Services-pa]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7abac94c-ba0e-415b-9196-72caf153cc7c&name=7abac94c-ba0e-415b-9196-72caf153cc7c-01.jpg)
![Clorazepate Dipotassium (Clorazepate Dipotassium) Tablet [Remedyrepack Inc. ]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=569f3007-0faf-41c2-991c-66ff0779810b&name=MM2.jpg)
![Clorazepate Dipotassium Tablet [Taro Pharmaceuticals U.s.a., Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=499a6989-8912-44b7-b1eb-ee8f85ae378f&name=clorazepate-02.jpg)
![Clorazepate Dipotassium Tablet [Pd-rx Pharmaceuticals, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=54722d55-d620-488f-87eb-e1e3b129c2f9&name=43063030.jpg)
![Clorazepate Dipotassium Tablet [Pd-rx Pharmaceuticals, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d686bb2-3901-4f78-aac7-bf2b83824765&name=43063350.jpg)
![Clorazepate Dipotassium Tablet [Mylan Pharmaceuticals Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9acbb3f4-4bf6-40ae-89e3-303ec167912c&name=1afe1d2f-2d5a-4348-bbe0-e20cb060d1fc-02.jpg)
![Clorazepate Dipotassium Tablet [Ranbaxy Pharmaceuticals Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6e9edbfc-1950-4893-9d38-e82b119ddb9a&name=clorazep1.jpg)
![Clorazepate Dipotassium Tablet [Bryant Ranch Prepack]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d57138fd-067d-43f8-80d5-9190cf90ef3d&name=36461.jpg)
![Clorazepate Dipotassium Tablet [Bryant Ranch Prepack]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53c7a271-e511-457f-9c3e-afd84a1c85f1&name=38581.jpg)
![Clorazepate Dipotassium Tablet [Bryant Ranch Prepack]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5a82b479-64bd-474f-93e2-c97ce5cce9df&name=38591.jpg)
![Clorazepate Dipotassium Tablet [Pd-rx Pharmaceuticals, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0972f807-b171-4059-8299-6f51f71d92d1&name=43063382.jpg)
![Clorazepate Dipotassium Tablet [A-s Medication Solutions Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=529a1c6c-4c8e-4f6d-aa84-3529f839a5ad&name=4586-1.jpg)
![Clorazepate Dipotassium Tablet [American Health Packaging]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b8fbc985-62a5-4bc2-b9b8-0451926e86de&name=ClorazepateDipotassiumTabletsUSP,3.75mglabel.jpg)
Login To Your Free Account